XML 39 R5.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands
6 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Cash flows from operating activities:    
Net loss $ (72,415) $ (6,647)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 7,649 8,334
Stock-based compensation 9,682 8,105
Other non-cash transactions 620 (205)
Changes in operating assets and liabilities:    
Accounts receivable 16,642 (4,645)
Inventory (2,531) (3,306)
Other assets (2,191) (136)
Accounts payable (3,149) 2,183
Accrued compensation 183 (2,144)
Accrued expenses 2,371 1,012
Accrued clinical trial expenses 1,688 (818)
Deferred revenue (7,549) (55,120)
Other liabilities (658) (729)
Net cash used in operating activities (49,658) (54,116)
Cash flows from investing activities:    
Purchases of investments (509,681) (218,275)
Sales of investments 180,478 8,197
Maturities of investments 156,962 241,256
Purchases of property and equipment (6,845) (8,796)
Net cash (used in) provided by investing activities (179,086) 22,382
Cash flows from financing activities:    
Payments of loan and capital lease obligations (934) (731)
Issuance of common stock, net of issuance costs 223,549 6,148
Net cash provided by financing activities 222,615 5,417
Effect of exchange rates on cash and cash equivalents 0 (36)
Net decrease in cash and cash equivalents (6,129) (26,353)
Cash and cash equivalents at beginning of period 17,755 49,597
Cash and cash equivalents at end of period $ 11,626 $ 23,244